

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/669,082	09/25/2000	Richard L. Scopp	6734.US.O1	3368
23492	7590 04/28/2005		EXAMINER	
ROBERT DEBERARDINE			DO, PENSEE T	
	ABORATORIES T PARK ROAD		ART UNIT	PAPER NUMBER
DEPT. 377/AP6A			1641	
ABBOTT PARK, IL 60064-6008			DATE MAILED: 04/28/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	09/669,082	SCOPP ET AL.					
Office Action Summary	Examiner	Art Unit	_				
	Pensee T. Do	1641					
The MAILING DATE of this communication Period for Reply	appears on the cover sheet w	th the correspondence address					
A SHORTENED STATUTORY PERIOD FOR RETHE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communication - If the period for reply specified above is less than thirty (30) days, and If NO period for reply specified above, the maximum statutory period for reply within the set or extended period for reply will, by standard patent term adjustment. See 37 CFR 1.704(b).	ON. R 1.136(a). In no event, however, may a r n. a reply within the statutory minimum of thir eriod will apply and will expire SIX (6) MON latute, cause the application to become AE	eply be timely filed by (30) days will be considered timely. THS from the mailing date of this communication. SANDONED (35 U.S.C. § 133).					
Status		,					
1) Responsive to communication(s) filed on 1	1 February 2005.						
2a)⊠ This action is FINAL . 2b)□							
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4) ⊠ Claim(s) <u>1,2,4-17 and 26</u> is/are pending in 4a) Of the above claim(s) is/are with 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) <u>1, 2 4-17, 26</u> is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction are	drawn from consideration.						
Application Papers							
9)☐ The specification is objected to by the Exam	niner.	·					
10) The drawing(s) filed on is/are: a)	accepted or b)□ objected to	by the Examiner.					
Applicant may not request that any objection to	the drawing(s) be held in abeyar	ice. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the contact the contact and the contact	· ·	•					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for fore a) All b) Some * c) None of: 1. Certified copies of the priority documed 2. Certified copies of the priority documed 3. Copies of the certified copies of the priority documed application from the International But * See the attached detailed Office action for a	nents have been received. Idents have been received in A Derionity documents have been Ireau (PCT Rule 17.2(a)).	pplication No received in this National Stage					
Attachment(s)		,					
1) D Notice of References Cited (PTO-892)		ummary (PTO-413)					
 Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB Paper No(s)/Mail Date)/Mail Date formal Patent Application (PTO-152) 					

Art Unit: 1641

DETAILED ACTION

Withdrawn Rejection(s)

The rejection under 35 USC 102 in the previous office action is withdrawn herein. (this art rejection should have been withdrawn in the previous office action because Applicants have narrowed down claim 1 to include polylysine, polyornithine, polybrene or dimethyldiallylammonium chloride).

Maintained Rejection(s)

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1, 2, 4-17 and 26 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The present specification fails to disclose the "unconjugated" large polycation as recited in the claims. The claims now recite adding an "unconjugated" large polycation in a sample to decrease interferences. However, the present specification fails to teach an "unconjugated" polycation. The present specification only teaches a large polycation. It does not teach an "unconjugated" large polycation. Thus, one of ordinary skills in the art would not assume that such large polycation is an "unconjugated" large polycation.

Application/Control Number: 09/669,082

Art Unit: 1641

Description and clear support of an "unconjugated" large polycation is required in the specification.

Furthermore, the amendment to the specification filed on February 11, 2005 fails to put the claims in condition for allowance. Rather, it creates a new matter issue.

Response to Arguments

Applicant's arguments filed February 11, 2005 have been fully considered but they are not persuasive.

Applicants have amended the specification by adding a sentence "therefore, the polycation is unconjugated" to overcome the 112, 1st rejection (lack of description).

Applicants further argue that there are supports in the specification for "unconjugate polycation", i.e. the polycation can be added during the immunoassay as a separate reagent" and "the polycation can be incorporated into an assay specific diluent".

Applicants also pointed out supports in the examples that the polycation does not bind to any label or ligand in an assay.

The supports for an "unconjugated" polycation pointed out by Applicants are not persuasive. A polycation conjugated to some molecule other than a ligand for binding the analyte or a label, can be added as a "separate reagent" in assay. The polycation can be conjugated to a substrate for the enzyme label in the assay. Such conjugate can be added as a "separate reagent" in an assay or can be incorporated into an assay specific diluent. The specification fails to describe that the polycation added as a separate reagent is conjugated or unconjugated; or that the polycation is incorporated into the assay specific diluent as conjugated or unconjugated. Furthermore, regarding

Application/Control Number: 09/669,082

Art Unit: 1641

Applicants' arguments about the examples, that the anti-TSH antibody is conjugated to the TSH and not the polycations or that an acridinium label is conjugated to the antialpha TSH and not the polycation, the polycation does not have to be conjugated to the acridinium label or the TSH or the anti-TSH antibody. In fact, it can be conjugated to other molecules such as a substrate for an enzyme label and together the conjugate is added as a separate reagent.

Allowable Subject Matter

Claims 1, 2, 4-17 and 26 are allowed over the prior arts.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Pensee T. Do whose telephone number is 571-272-0819. The examiner can normally be reached on Monday-Friday, 7:00-3:00.

Application/Control Number: 09/669,082

Art Unit: 1641

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Pensee T. Do Patent examiner April 22, 2005

CHRISTOPHER L. CHIN PRIMARY EXAMINER GROUP 1809-7647

4/26/05

Christoph L. Chri